|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 16/09/14 | CHUGAI PHARMACEUTICAL : Roche's $8 billion InterMune buy not a signal for more big deals | RE |
| 04/09/14 | Roche : rules out mega deals, open to smaller ones - paper | RE |
Executive Committee: InterMune Inc
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Chief Tech/Sci/R&D Officer | 71 | 01/04/2002 | |
Carla Fiankan
LAW | General Counsel | - | 01/08/2011 |
Company details: InterMune Inc
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | -6.35% | -4.87% | +9.03% | 46.05B | |
| +0.66% | -2.78% | +341.59% | +521.20% | 43.59B | |
| +1.25% | -2.76% | +36.54% | +20.92% | 42.35B | |
| +1.33% | -3.24% | +3.27% | +65.67% | 38.86B | |
| -1.44% | -4.76% | +10.26% | +38.52% | 32.24B | |
| +0.88% | -2.58% | - | - | 17.16B | |
| +1.05% | -0.36% | +18.40% | +110.90% | 16.28B | |
| -0.31% | -2.78% | +10.47% | +30.49% | 14.32B | |
| +1.27% | -4.15% | +73.10% | +38.49% | 13.03B | |
| Average | +0.34% | -4.76% | +61.10% | +104.40% | 29.32B | |
| Weighted average by Cap. | +0.22% | -5.10% | +73.25% | +123.85% |
- Stock Market
- Stocks
- Stock
- Company InterMune Inc
Select your edition
All financial news and data tailored to specific country editions
